BTK and Miyoshi myopathy: Additional work has demonstrated that BTK inhibitor ibrutinib can inhibit NF-κB and that this effect is responsible for ibrutinib enhancing the cytotoxicity of bortezomib in MM models (Rushworth et al., 2013).